AKT1 and breast cancer: As such, targeted therapies play an important role, particularly in the PIK3/AKT pathway, with PIK3CA mutations prevalent in HR+ breast cancer (34.5%) and AKT1 and PTEN mutations restricted to this subgroup [215].